Immune checkpoint inhibitors - Globe Thesis

Keyword [Immune checkpoint inhibitors] Result: 1 - 20 \| Page: 1 of 6
1.	Synergistic Effects Of The Immune Checkpoint Inhibitor CTLA-4 Combined With The Growth Inhibitor Lycorine In A Mouse Model Of Renal Cell Carcinoma
2.	Genomic Alterations Of Hepatocellular Carcinoma By Panel-based Sequencing
3.	Research Progress On The Application Of Immunotherapy In Multiple Myeloma
4.	Preparation Of Injectable Hydrogel Tumor Vaccine And Study Of Its Effect On Tumor Immunotherapy
5.	Prognostic And Predictive Roles Of TMB And CNA Across Metastatic Pan-cancer:immunotherapeutic Implications
6.	Part 1:clinical Observation Of Immune Checkpoint Inhibitors In The Treatment Of Advanced Pancreatic Cancer And Biliary Tract Cancer Part 2:the Expression Of Notch Signaling Pathway Related Proteins In SCLC
7.	Synergistic Effect Of Radiofrequency Ablation And Immune Checkpoint Inhibitors On Advanced Kidney Cancer And Its Imaging Evaluation
8.	Efficacy Evaluation And Candidate Biomarkers Screening For Anti-PD-1 Therapy In Advanced Lung Cancer
9.	Toxicities And Management Of Immune Checkpoint Inhibitors In Cancer Immunotherapy
10.	Post-marketing Study Of Safety Of Immune Checkpoint Inhibitor Based On Spontaneous Reporting System
11.	New Progress Of Immune Checkpoint Inhibitors In The Treatment Of Lung Cancer
12.	The Efficacy And Safety Of PD-1/PD-L1 Inhibitors Versus Chemotherapy In The Treatment Of Non Small Cell Lung Cancer-a Meta Analysis
13.	The Incidence And Risk Factors Of Pneumonitis In Patients Treated With Immune Checkpoint Inhibitors
14.	Efficacy And Immune-related Adverse Events Induced By PD-1/PD-L1 And CTLA-4 Inhibitors In Advanced NSCLC
15.	Efficacy Of PD-1/PD-L1 Immune Checkpoint Inhibitors For Advanced Nsclc According To PD-L1 Expression: A Meta-analysis
16.	Clinical Pathological Characteristics Of Liver Injury Associated With Immune Checkpoint Inhibitors
17.	The Role Of Immunotherapy In Advanced Non-Small Cell Lung Cancer With Driver Gene Mutations
18.	Indirect Comparison Between Immune Checkpoint Inhibitors And Immune Checkpoint Inhibitors Plus Chemotherapy As First-line Treatment For Advanced Non-small Cell Lung Cancer:A Systematic Review
19.	Risk Of Immune-Related Adverse Events Associated With Ipilimumab-Plus-Nivolumab And Nivolumab Therapy In Cancer Patients
20.	Adverse Events Associated With Immune Checkpoint Inhibitors For Solid Tumor:A Systematic Review And Meta-analysis
<<First <Prev Next> Last>> Jump to